title: Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
abstract: BACKGROUND
  Two different enzyme preparations, agalsidase alfa (Replagal(TM), Shire) and beta (Fabrazyme(TM), Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized controlled open label trial.
  
  
  RESULTS
  Thirty-four Fabry disease patients were treated with either agalsidase alfa or agalsidase beta at equal dose of 0.2 mg/kg biweekly. Primary endpoint was reduction in left ventricular mass after 12 and 24 months of treatment. Other endpoints included occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), glomerular filtration rate, pain, anti-agalsidase antibodies, and globotriaosylceramide levels in plasma and urine. After 12 and 24 months of treatment no reduction in left ventricular mass was seen, which was not different between the two treatment groups. Also, no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. Antibodies developed only in males (4/8 in the agalsidase alfa group and 6/8 in the agalsidase beta group). Treatment failure within 24 months of therapy was seen in 8/34 patients: 6 male patients (3 in each treatment group) and 2 female patients (both agalsidase alfa). The occurrence of treatment failures did not differ between the two treatment groups; chi(2) = 0.38 p = 0.54.
  
  
  CONCLUSIONS
  Our study revealed no difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly. Treatment failure occurred frequently in both groups and seems related to age and severe pre-treatment disease.
  
  
  BACKGROUND
  International Standard Randomized Clinical Trial ISRCTN45178534 [http://www.controlled-trials.com/ISRCTN45178534].
authors.affiliation: Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, Netherlands; Department of Medical Biochenmistry, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands.
authors.forename: Anouk C
authors.initials: AC
authors.lastname: Vedder
authors.forename: Gabor E
authors.initials: GE
authors.lastname: Linthorst
authors.forename: Gunnar
authors.initials: G
authors.lastname: Houge
authors.forename: Johannna E M
authors.initials: JE
authors.lastname: Groener
authors.forename: Els E
authors.initials: EE
authors.lastname: Ormel
authors.forename: Berto J
authors.initials: BJ
authors.lastname: Bouma
authors.forename: Johannes M F G
authors.initials: JM
authors.lastname: Aerts
authors.forename: Asle
authors.initials: A
authors.lastname: Hirth
authors.forename: Carla E M
authors.initials: CE
authors.lastname: Hollak
mesh_terms: D000906:Antibodies / Q000097:blood / Q000652:urine; D002552:Cerebral Ventricles / Q000033:anatomy & histology / Q000187:drug effects / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D000795:Fabry Disease / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D010147:Pain Measurement; D018579:Patient Selection; D011897:Random Allocation; D011994:Recombinant Proteins; D020521:Stroke / Q000139:chemically induced; D017211:Treatment Failure; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase; C459420:agalsidase beta